In this week’s EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool–which could rise to €100 million–in up to 15 early-stage biotechs. And more.

…read more

Source: Dutch VC opens €65M cancer fund, Affimed IPO falls short, Evotec begins legal action


0 No comments